IceCure's ProSense® Substantially Reduces Abdominal Wall Endometriosis Pain with High Procedural Efficacy

Core Insights - IceCure Medical's ProSense® cryoablation technology shows significant efficacy in treating symptomatic abdominal wall endometriosis, with pain scores declining from a median of 8 to 0 after treatment [1][4][8] - The technology is FDA cleared and approved in the EU for gynecological indications, indicating its regulatory acceptance and potential marketability [1][4] Study Findings - The independent study published in the Journal of Personalized Medicine involved 14 patients with 23 AWE lesions, treated between September 2022 and April 2025 [3] - Key results include a median pain score reduction from 8/10 (range: 6–10) pre-treatment to 0/10 (range: 0–2) at 3-month follow-up, with a p-value of < 0.0001, confirming statistical significance [8] - MRI confirmed complete coverage of the ablation zone and disappearance of hemorrhagic inclusions in all cases, indicating high procedural efficacy [8] Patient and Provider Benefits - ProSense® enhances patient and provider value by accelerating recovery, reducing pain, and minimizing surgical risks and complications [6][7] - The median ablation and overall procedural times were reported as 15 minutes and 93 minutes, respectively, showcasing the efficiency of the procedure [8] - No peri- or post-procedural complications were reported, and no visible scars were observed, highlighting the safety and cosmetic advantages of the procedure [8] Market Context - Endometriosis affects approximately 10% of women of reproductive age globally, translating to about 190 million individuals, indicating a substantial market for effective treatments [5] - AWE has an incidence rate of 0.03% - 3.5% among women, further emphasizing the need for effective management options [5]